Overnutrition characterized by overconsumption of food rich in fat and carbohydrates is a significant contributor to hypertension, type 2 diabetes, and the cardiorenal syndrome. Overnutrition activates the renin-angiotensin-aldosterone system (RAAS) and causes chronic exposure of cardiovascular and renal tissue to increased circulating nutrients, insulin (INS), and angiotensin II (ANG II). Emerging evidence suggests that overnutrition, aldosterone, and ANG II promote INS resistance, a chronic condition that underlies these co-morbidities, through activation of the mammalian target of the rapamycin (mTOR)/S6 kinase 1 (S6K1) signaling pathway in cardiovascular tissue and the kidney. However, a novel ANG II type 2 receptor (AT 2 R)-mediated cross talk between the RAAS and mTOR pathways ameliorates overnutrition-induced activation of mTOR/S6K1 signaling in cardiovascular tissue of rats, mice, and humans and confers cardioprotection.
Introduction
Diminished insulin (INS) metabolic signaling is a common feature of disease states such as obesity, hypertension, diabetes, and the cardiorenal metabolic syndrome (CRS). Overnutrition (especially that characterized by excess intake of fat and carbohydrates) is a major Published online: April 15, 2011 Lakshmi Pulakat, PhD D109 HSC Diabetes Center One Hospital Drive, Columbia, MO 65212 (USA) Tel. +1 573 884 0769, E-Mail pulakatl @ health.missouri.edu pertrophy and increases protein synthesis in VSMCs [30] [31] [32] . Thus, AT 1 R-induced mTOR/ S6K1 activation interferes with INS metabolic signaling and biological responses in CV as well as other tissues.
CV Effects of Overnutrition and RAAS (mTOR/S6K1)-Mediated INS Resistance
INS induces vasodilation by enhancing Akt stimulation of eNOS(P) activation and NO production. The role of INS-stimulated IRS-1 tyrosine (Tyr) (P) in mediating eNOS activation is underscored by the observation that IRS-1 overexpression in aortic endothelial cells increases NO production [33] , and introduction of a mutant IRS-1 unable to bind to the p85 subunit of PI3-K [33] reduces INS-stimulated NO production. In VSMC, ANG II increases intracellular calcium ([Ca 2+ ] i ) and promotes MLC kinase activation [34] . INS decreases ANG II-induced increases in VSMC [Ca 2+ ] i and MLC kinase activity [1] . INS normally promotes myocardial glucose uptake and utilization, mechanical-electrical coupling and diastolic relaxation via signaling through the IRS-1/PI3-K/Akt pathway [35] [36] [37] ( fig. 2 ). INS metabolic signaling increases coronary vessel NO production which, in turn, contributes to the beneficial effects of INS on glucose uptake, coronary blood flow, and diastolic relaxation [36] [37] [38] [39] [40] [41] . These observations suggest coupling between the metabolic and coronary vascular actions of INS metabolic signaling in the heart. These beneficial cardiac effects of INS metabolic signaling are decreased in states of INS resistance [37] [38] [39] [40] [41] [42] [43] [44] . We have observed ANG II-induced inhibition of NO production can be reversed by inhibition of mTOR/S6K1 in endothelial cells. Cardiomyocytes and cardiac fibroblasts express high-affinity AT 1 R [10] and many of the adverse effects of ANG II are due to AT 1 R-mediated signaling.
To evaluate the cardiac functional effects of INS metabolic signaling we utilize positron emission tomography (PET). In the INS-resistant state, myocardial glucose uptake and metabolism is impaired, leading to diastolic dysfunction, attenuated myocardial blood flow, and impaired ischemic reconditioning. PET imaging, using 18 F-deoxyglucose ( 18 FDG), is used to evaluate INS-stimulated glucose uptake ( fig. 3 ) [41, 45] . We have utilized magnetic resonance imaging in conditions of overnutrition and excessive tissue RAAS activation, and have demonstrated impaired/prolonged diastolic relaxation [7] . We have further demonstrated that both impaired INS-stimulated glucose uptake and diastolic dysfunction are related to impaired systemic and myocardial INS metabolic signaling in models of obesity and increased tissue RAAS expression [2, 7] . Interestingly, we have also observed that drug treatments that improved INS resistance in rodent models of overnutrition attenuated mTOR/ S6K1 signaling. Collectively, these observations indicate that a combination of enhanced tissue RAAS activation and a westernized high-sucrose/high-fat diet will reduce INS metabolic signaling and enhance mTOR/S6K1 activation to a greater extent than either intervention alone.
AT2R } mTOR Signaling Loop in Overnutrition, Hyperinsulinemia, and Excess RAAS Activation
Accumulating evidence suggests that AT 2 R is a modulator of cardiac pathology [46] [47] [48] [49] [50] [51] . AT 2 R is up-regulated in failing human hearts [50] , the vasculature of diabetic patients [47] , and animal models of INS resistance, myocardial infarction, senescence, and hyperinsulinemia [49, 52] . AT 2 R signaling reduces fibroblast growth and myocardial hypertrophy [53] . The suppression of AT 2 R activation interferes with anti-hypertrophic/anti-fibrotic effects of AT 1 R blockade in experimental myocardial infarction [54] [55] [56] [57] [58] . In cardiomyocyte-specific AT 2 R transgenic mice, moderate overexpression of AT 2 R in ventricular myocytes is cardioprotective under conditions of pressure overload induced by aortic banding [54] . On the other hand, excessive AT 2 R overexpression in ventricular myocytes leads to dilated cardiomyopathy [56] .
Signaling pathways that increase AT 2 R protein in cardiac pathology are not well understood. Interestingly, hyperinsulinemia-induced cardiac hypertrophy is accompanied by a reduction in AT 1 R, an increase in AT 2 R, and activation of S6K1 via the PI3-K/Akt signaling pathway [57] . The association between increases in AT 2 R protein and S6K1 activation in INSinduced cardiac hypertrophy prompts us to posit that mTOR/S6K1-induced increases in translation could, in part, contribute to increases in AT 2 R protein levels. Thus, conditions that activate mTOR-mediated signaling in cardiac tissue could also elevate AT 2 R protein levels [58] [59] [60] . Activated mTOR nucleates two large protein complexes, mTOR-Raptor complex 1 (mTORC1) and mTOR-Rictor complex 2 (mTORC2) that mediate mTOR signaling. When associated with Raptor, mTOR functions as the physiological Thr 389 kinase for its substrate S6K1 [61, 62] . Ribosomal protein S6 (RPS6) is a substrate of S6K1 and a key factor for protein synthesis in various cell types [62, 63] . Thus, activation of mTOR/S6K1 increases translation of different proteins via the S6K1-RPS6 pathway. The second substrate of mTOR is 4E-BP, which in its hypophosphorylated form functions as a translational repressor by binding to translation initiation factor eIF4E. In this context, mTORC1 enhances protein synthesis by inhibitory phosphorylation of 4E-BP on Thr 37 and Thr 46 . Interestingly, hyperinsulinemia-induced cardiac hypertrophy is accompanied by a reduction in AT 1 R, an increase in AT 2 R, and activation of S6K1 [57] . The association between increases in AT 2 R protein and S6K1 activation in INS-induced cardiac hypertrophy prompted us to posit the existence of an mTOR-S6K1 } AT 2 R signaling loop that may serve to protect the heart during conditions of overnutrition.
We have recently shown that the ZO rat, a genetic model for overnutrition and the CRS, has significant maladaptive changes in cardiac tissue [2, 7, 10] . The ZO rat heart exhibits prolonged diastolic relaxation time and reduced initial diastolic filling rate as well as increased interstitial and pericapillary fibrosis, and elevated 3-nitrotyrosine and NADPH oxidase-dependent superoxide production compared to heart tissue of syngeneic Zucker lean (ZL) controls [7] . Since overnutrition, a predicted activator of mTOR, is the key contributor for cardiac pathology in this model system, we tested for co-existence of mTOR-mediated signaling and elevation of AT 2 R in the left ventricle of the ZO rat heart. Our recent data show increased cardiac activation of mTOR signaling, characterized by downstream activation of RPS6 and inhibition of 4E-BP in hypertrophic hearts of 12-week-old ZO rats, which manifest diastolic dysfunction. Moreover, in the ZO rat heart, AMP kinase, normally a compensatory negative modulator of mTOR, remained unactivated in ZO compared to ZL cardiac tissue. Second, as in the case of failing human hearts, we observed that dysfunctional, hypertrophied ZO rat hearts exhibited an increase in AT 2 R protein levels. Since AT 2 R functions as a cell growth inhibitor and has cardioprotective effects, this observation suggests that the increase in the AT 2 R protein can be a downstream event of mTOR-S6K1 signaling and the subsequent increase in translation ( fig. 4 ) . Additionally, we observed that chronic exposure 
Impact of Overnutrition and mTOR Signaling on the Kidney
There is emerging evidence that the mTOR/S6K1 pathway is involved in a spectrum of kidney diseases, including that of diabetic kidney disease [64] [65] [66] [67] [68] [69] [70] . Diabetic kidney disease is often characterized by progression of albuminuria to proteinuria and a gradual but progressive decline in glomerular filtration rate [71, 72] . Many individuals who are destined to develop diabetic kidney disease manifest the clinical characteristics of the CRS prior to the development of overt diabetes [72] . In evolving through the renal abnormalities character- izing the CRS to that of diabetic kidney disease, the morphological process is characterized by glomerular hypertrophy and hyperfiltration, podocyte loss and associated glomerulosclerosis, and finally progressive tubulointerstitial fibrosis [72] . The initial hypertrophic process is likely mediated by overnutrition and RAAS stimulation of the mTOR signaling pathway [64, 70, 73] . The mTOR molecule is a large protein with many domains, and when complexed with G ␤ L and Raptor (regulatory-associated protein of mTOR) it forms the rapamycin-sensitive complex referred to as mTORC1 [35, 44, 63] . The activity of mTORC1 appears to be regulated through a dynamic interaction between mTOR and Raptor mediated by G ␤ L. While the initial hypertrophic and proliferative lesions in diabetic kidney disease are now thought to occur through mTOR, the regulatory role of S6K1, the substrate of mTORC1, in the kidney appears to occur through promotion of proximal tubule epithelial cell fibrosis [64] [65] [66] [67] [68] [69] [70] . Recent data suggest that targeting reductions in mTOR activity by targeting mTORC1 and S6K1 with rapamycin treatment improves tubulointerstitial fibrosis and proteinuria in rodent models of diabetic nephropathy and polycystic kidney disease [64] [65] [66] [67] [68] [69] [70] .
Rapamycin is clinically used to suppress rejection of transplanted organs. In addition to its immunosuppressive actions, rapamycin inhibits growth factor-mediated proliferation and promotes survival of many non-immune cells, including renal tubular cells and fibroblasts [64] [65] [66] [67] [68] [69] [70] [73] [74] [75] . There is increasing interest in using rapamycin to promote prolonged survival in aging as well as expanding its use in chronic disease management.
Recent data suggest that aldosterone stimulates proliferation of mesangial cells [76] , in part through downstream mTOR/S6K1 signaling [76] . Tubulointerstitial fibrosis is the critical mechanism by which tubular atrophy and loss of nephron mass occur and thereby promote progressive kidney disease [77, 78] . In young rodent models of kidney disease, ANG II has been shown to induce epithelial-mesenchymal transition (EMT) through actions on the AT 1 R in the proximal tubule, a process that leads to tubulointerstitial fibrosis [79] [80] [81] [82] .
EMT and disruption of adhesion molecules contribute to tubulointerstitial fibrosis [83, 84] . EMT is a phenotypic conversion with loss of epithelial cell-basement membrane adherens junctions and acquisition of a fibroblastic phenotype. Disruption of adhesion molecules is the first phase of EMT that results in tissue fibrosis [85] [86] [87] . Recent evidence has established EMT as a critical initial mechanism for tubulointerstitial fibrosis in humans and other species. Tubulointerstitial fibrosis is characterized by loss of differentiated epithelial cells and activation of renal fibroblasts leading to fibrosis. Under unstressed, basal conditions, proximal tubule cells are attached to each other and to the basement membrane through specialized junctional complexes (adherens junctions) that include molecules such as cadherin. During injury, epithelial cells lose polarity and the mechanisms of adhesion. The beststudied cadherin in the promotion of EMT is E-cadherin, which typically resides in epithelial tissue; however, it is not found in human proximal tubule cells. Recent data suggest the cadherin in the kidney and specific to the proximal tubule is N-cadherin [87, 88] . N-cadherin in the proximal tubule has been shown to bind cytoskeletal components that provide a structural foundation for adherens junctions. Of note, cadherins not only function as static structural components of adherens junctions but also play a role in cell signaling pathways [88] . Alterations in cadherin expression have been studied in various carcinogenesis models to understand the mechanism of EMT in the fibrotic process [83] [84] [85] . Recent evidence further indicates the mTOR pathway is a critical player in the progression of tubulointerstitial fibrosis to progressive kidney disease [64] [65] [66] [67] [68] [69] [70] . Therefore, the collective evidence from rodent and culture models further suggests targeting reductions in RAAS activity may slow progressive kidney disease through potential mechanisms that improve cadherin expression as well as promote survival [10] ( fig. 5 ).
Disclosure Statement
The authors have no conflict of interest. 
